How I manage patients with hairy cell leukaemia

British Journal of Haematology

Volumn 177, Issue 4, 2017, Pages 543-556

  Thompson, Philip A ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

hairy cell leukaemia; hairy cell leukaemia variant; novel therapies; purine analogues

Indexed keywords

ALPHA INTERFERON; ANTIBODY DRUG CONJUGATE; B RAF KINASE; BENDAMUSTINE; BL 22; BRUTON TYROSINE KINASE INHIBITOR; CD22 ANTIGEN; CLADRIBINE; DABRAFENIB; FILGRASTIM; FLUDARABINE; GLUTAMIC ACID; IBRUTINIB; INTERLEUKIN 2 RECEPTOR ALPHA; MOXETUMOMAB PASUDOTOX; PENTOSTATIN; PURINE DERIVATIVE; RITUXIMAB; TRAMETINIB; UNCLASSIFIED DRUG; VALINE; VEMURAFENIB; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; IMMUNOLOGIC FACTOR; PURINE NUCLEOSIDE; TUMOR MARKER;

ACUTE MYELOID LEUKEMIA; AREA UNDER THE CURVE; ARTHRALGIA; BONE MARROW BIOPSY; BONE MARROW SUPPRESSION; BRAF GENE; CANCER INCIDENCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; COLON ADENOCARCINOMA; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DRUG CYTOTOXICITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG MECHANISM; DRUG RESISTANCE; DRUG RESPONSE; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; FLU LIKE SYNDROME; GENE MUTATION; HAIRY CELL LEUKEMIA; HAND FOOT SYNDROME; HEMOLYTIC UREMIC SYNDROME; HERPES ZOSTER; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; INFECTION; INFUSION RELATED REACTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKEMOGENESIS; LYMPHOCYTOPENIA; MELANOMA; METASTATIC MELANOMA; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NON MELANOMA SKIN CANCER; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PHOTOSENSITIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RASH; REVIEW; SECOND CANCER; SPLENECTOMY; THROMBOCYTOPENIA; THYROID CANCER; TREATMENT OUTCOME; VERRUCA VULGARIS; COMPLICATION; GENETICS; LEUKEMIA, HAIRY CELL; METABOLISM; MUTATION; PROCEDURES; SOCIAL SUPPORT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CLADRIBINE; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-ALPHA; LEUKEMIA, HAIRY CELL; MUTATION; OPPORTUNISTIC INFECTIONS; PENTOSTATIN; PROTO-ONCOGENE PROTEINS B-RAF; PURINE NUCLEOSIDES; RITUXIMAB; SOCIAL SUPPORT; SPLENECTOMY; TREATMENT OUTCOME;

EID: 85011607388     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14524     Document Type: Review

References (95)

1. Andrulis, M., Penzel, R., Weichert, W., von Deimling, A. & Capper, D. (2012) Application of a BRAF V600E mutation-specific antibody for the diagnosis of hairy cell leukemia. The American Journal of Surgical Pathology, 36, 1796–1800.
2. Anonymous. (1987) Consensus resolution: proposed criteria for evaluation of response to treatment in hairy cell leukemia. Leukemia, 1, 405.
3. Arons, E., Margulies, I., Sorbara, L., Raffeld, M., Stetler-Stevenson, M., Pastan, I. & Kreitman, R.J. (2006) Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clinical Cancer Research, 12, 2804–2811.
4. Arons, E., Suntum, T., Stetler-Stevenson, M. & Kreitman, R.J. (2009) VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood, 114, 4687–4695.
5. Arons, E., Roth, L., Sapolsky, J., Suntum, T., Stetler-Stevenson, M. & Kreitman, R.J. (2011) Evidence of canonical somatic hypermutation in hairy cell leukemia. Blood, 117, 4844–4851.
6. Berman, E., Heller, G., Kempin, S., Gee, T., Tran, L.L. & Clarkson, B. (1990) Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood, 75, 839–845.
7. Bosch, F., Abrisqueta, P., Villamor, N., Terol, M.J., Gonzalez-Barca, E., Ferra, C., Gonzalez Diaz, M., Abella, E., Delgado, J., Carbonell, F., Garcia Marco, J.A., Escoda, L., Ferrer, S., Monzo, E., Gonzalez, Y., Estany, C., Jarque, I., Salamero, O., Muntanola, A. & Montserrat, E. (2009) Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. Journal of Clinical Oncology, 27, 4578–4584.
8. Bottcher, S., Ritgen, M., Fischer, K., Stilgenbauer, S., Busch, R.M., Fingerle-Rowson, G., Fink, A.M., Buhler, A., Zenz, T., Wenger, M.K., Mendila, M., Wendtner, C.M., Eichhorst, B.F., Dohner, H., Hallek, M.J. & Kneba, M. (2012) Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. Journal of Clinical Oncology, 30, 980–988.
9. Bouroncle, B.A., Wiseman, B.K. & Doan, C.A. (1958) Leukemic reticuloendotheliosis. Blood, 13, 609–630.
10. Burger, J.A., Tedeschi, A., Barr, P.M., Robak, T., Owen, C., Ghia, P., Bairey, O., Hillmen, P., Bartlett, N.L., Li, J., Simpson, D., Grosicki, S., Devereux, S., McCarthy, H., Coutre, S., Quach, H., Gaidano, G., Maslyak, Z., Stevens, D.A., Janssens, A., Offner, F., Mayer, J., O'Dwyer, M., Hellmann, A., Schuh, A., Siddiqi, T., Polliack, A., Tam, C.S., Suri, D., Cheng, M., Clow, F., Styles, L., James, D.F. & Kipps, T.J. (2015) Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. New England Journal of Medicine, 373, 2425–2437.
11. Burotto, M., Stetler-Stevenson, M., Arons, E., Zhou, H., Wilson, W. & Kreitman, R.J. (2013) Bendamustine and rituximab in relapsed and refractory hairy cell leukemia. Clinical Cancer Research, 19, 6313–6321.
12. Byrd, J.C., Peterson, B.L., Morrison, V.A., Park, K., Jacobson, R., Hoke, E., Vardiman, J.W., Rai, K., Schiffer, C.A. & Larson, R.A. (2003) Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood, 101, 6–14.
13. Byrd, J.C., Furman, R.R., Coutre, S.E., Flinn, I.W., Burger, J.A., Blum, K.A., Grant, B., Sharman, J.P., Coleman, M., Wierda, W.G., Jones, J.A., Zhao, W., Heerema, N.A., Johnson, A.J., Sukbuntherng, J., Chang, B.Y., Clow, F., Hedrick, E., Buggy, J.J., James, D.F. & O'Brien, S. (2013) Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 369, 32–42.
14. Byrd, J.C., Harrington, B., O'Brien, S., Jones, J.A., Schuh, A., Devereux, S., Chaves, J., Wierda, W.G., Awan, F.T., Brown, J.R., Hillmen, P., Stephens, D.M., Ghia, P., Barrientos, J.C., Pagel, J.M., Woyach, J., Johnson, D., Huang, J., Wang, X., Kaptein, A., Lannutti, B.J., Covey, T., Fardis, M., McGreivy, J., Hamdy, A., Rothbaum, W., Izumi, R., Diacovo, T.G., Johnson, A.J. & Furman, R.R. (2016) Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. New England Journal of Medicine, 374, 323–332.
15. Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N., Caracciolo, F. & Petrini, M. (2004) Rituximab as treatment for minimal residual disease in hairy cell leukaemia. European Journal of Haematology, 73, 412–417.
16. Cervetti, G., Galimberti, S., Andreazzoli, F., Fazzi, R., Cecconi, N., Caracciolo, F. & Petrini, M. (2008) Rituximab as treatment for minimal residual disease in hairy cell leukaemia: extended follow-up. British Journal of Haematology, 143, 296–298.
17. Chadha, P., Rademaker, A.W., Mendiratta, P., Kim, B., Evanchuk, D.M., Hakimian, D., Peterson, L.C. & Tallman, M.S. (2005) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood, 106, 241–246.
18. Cheson, B.D., Sorensen, J.M., Vena, D.A., Montello, M.J., Barrett, J.A., Damasio, E., Tallman, M., Annino, L., Connors, J., Coiffier, B. & Lauria, F. (1998) Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. Journal of Clinical Oncology, 16, 3007–3015.
19. Chihara, D., Kantarjian, H., O'Brien, S., Jorgensen, J., Pierce, S., Faderl, S., Ferrajoli, A., Poku, R., Jain, P., Thompson, P., Brandt, M., Luthra, R., Burger, J., Keating, M. & Ravandi, F. (2016) Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial. British Journal of Haematology, 174, 760–766.
20. Clark, E.A. (1993) CD22, a B cell-specific receptor, mediates adhesion and signal transduction. The Journal of Immunology, 150, 4715–4718.
21. Daver, N., Nazha, A., Kantarjian, H.M., Haltom, R. & Ravandi, F. (2013) Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. Clinical Lymphoma, Myeloma & Leukemia, 13, 86–89.
22. Else, M., Ruchlemer, R., Osuji, N., Del Giudice, I., Matutes, E., Woodman, A., Wotherspoon, A., Swansbury, J., Dearden, C. & Catovsky, D. (2005) Long remissions in hairy cell leukemia with purine analogs: a report of 219 patients with a median follow-up of 12.5 years. Cancer, 104, 2442–2448.
23. Else, M., Osuji, N., Forconi, F., Dearden, C., Del Giudice, I., Matutes, E., Wotherspoon, A., Lauria, F. & Catovsky, D. (2007) The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia. Cancer, 110, 2240–2247.
24. Else, M., Dearden, C.E., Matutes, E., Garcia-Talavera, J., Rohatiner, A.Z., Johnson, S.A., O'Connor, N.T., Haynes, A., Osuji, N., Forconi, F., Lauria, F. & Catovsky, D. (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. British Journal of Haematology, 145, 733–740.
25. Falini, B., Tiacci, E., Liso, A., Basso, K., Sabattini, E., Pacini, R., Foa, R., Pulsoni, A., Dalla Favera, R. & Pileri, S. (2004) Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet, 363, 1869–1870.
26. Falini, B., Martelli, M.P. & Tiacci, E. (2016) BRAF-V600E mutation in hairy cell leukemia: from bench to bedside. Blood, 128, 1918–1927.
27. Flaherty, K.T., Infante, J.R., Daud, A., Gonzalez, R., Kefford, R.F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., Kudchadkar, R., Burris, 3rd, H.A., Falchook, G., Algazi, A., Lewis, K., Long, G.V., Puzanov, I., Lebowitz, P., Singh, A., Little, S., Sun, P., Allred, A., Ouellet, D., Kim, K.B., Patel, K. & Weber, J. (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New England Journal of Medicine, 367, 1694–1703.
28. Flinn, I.W., Kopecky, K.J., Foucar, M.K., Head, D., Bennett, J.M., Hutchison, R., Corbett, W., Cassileth, P., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F., Cheson, B. & Grever, M.R. (2000) Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood, 96, 2981–2986.
29. Forconi, F., Sozzi, E., Cencini, E., Zaja, F., Intermesoli, T., Stelitano, C., Rigacci, L., Gherlinzoni, F., Cantaffa, R., Baraldi, A., Gallamini, A., Zaccaria, A., Pulsoni, A., Gobbi, M., Tassi, M., Raspadori, D., Leoncini, L., Rinaldi, A., Sabattini, E., Bertoni, F., Pileri, S.A. & Lauria, F. (2009) Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. Blood, 114, 4696–4702.
30. Foucar, K., Falini, B., Catovsky, D. & Stein, H. (2008) Hairy cell leukaemia. In: World Health Organization Classification of Tumors of Haematopoietics and Lymphoid Tissues (eds by S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele & J.W. Vardiman), pp. 180–190. IARC Press, Lyon.
31. Gedik, E., Girgin, S., Aldemir, M., Keles, C., Tuncer, M.C. & Aktas, A. (2008) Non-traumatic splenic rupture: report of seven cases and review of the literature. World Journal of Gastroenterology, 14, 6711–6716.
32. Golomb, H.M. & Vardiman, J.W. (1983) Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood, 61, 349–352.
33. Golomb, H.M., Ratain, M.J., Fefer, A., Thompson, J., Golde, D.W., Ozer, H., Portlock, C., Silber, R., Rappeport, J., Bonnem, E., Spiegel, R., Tensen, L., Burke, J.S. & Vardiman, J.W. (1988) Randomized study of the duration of treatment with interferon alfa-2B in patients with hairy cell leukemia. Journal of the National Cancer Institute, 80, 369–373.
34. Goodman, G.R., Burian, C., Koziol, J.A. & Saven, A. (2003) Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. Journal of Clinical Oncology, 21, 891–896.
35. Grever, M.R. (2010) How I treat hairy cell leukemia. Blood, 115, 21–28.
36. Grever, M., Kopecky, K., Foucar, M.K., Head, D., Bennett, J.M., Hutchison, R.E., Corbett, W.E., Cassileth, P.A., Habermann, T., Golomb, H., Rai, K., Eisenhauer, E., Appelbaum, F. & Cheson, B.D. (1995) Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. Journal of Clinical Oncology, 13, 974–982.
37. Habermann, T.M. & Rai, K. (2011) Historical treatments of in hairy cell leukemia, splenectomy and interferon: past and current uses. Leukaemia & Lymphoma, 52, 18–20.
38. Hagberg, H. & Lundholm, L. (2001) Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. British Journal of Haematology, 115, 609–611.
39. Hisada, M., Chen, B.E., Jaffe, E.S. & Travis, L.B. (2007) Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study. Journal of the National Cancer Institute, 99, 215–222.
40. Hoffman, M.A., Janson, D., Rose, E. & Rai, K.R. (1997) Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. Journal of Clinical Oncology, 15, 1138–1142.
41. Honigberg, L.A., Smith, A.M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D.H., Miller, R.A. & Buggy, J.J. (2010) The bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proceedings of the National Academy of Sciences of the United States of America, 107, 13075–13080.
42. Huynh, E., Sigal, D. & Saven, A. (2009) Cladribine in the treatment of hairy cell leukemia: initial and subsequent results. Leukaemia & Lymphoma, 50, 12–17.
43. Jansen, J. & Hermans, J. (1981) Splenectomy in hairy cell leukemia: a retrospective multicenter analysis. Cancer, 47, 2066–2076.
44. Jehn, U., Bartl, R., Dietzfelbinger, H., Haferlach, T. & Heinemann, V. (2004) An update: 12-year follow-up of patients with hairy cell leukemia following treatment with 2-chlorodeoxyadenosine. Leukemia, 18, 1476–1481.
45. Juliusson, G., Heldal, D., Hippe, E., Hedenus, M., Malm, C., Wallman, K., Stolt, C.M., Evensen, S.A., Albertioni, F., Tjonnfjord, G., Lenkei, R. & Liliemark, J. (1995) Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. Journal of Clinical Oncology, 13, 989–995.
46. Kraut, E. (2011) Infectious complications in hairy cell leukemia. Leukaemia & Lymphoma, 52, 50–52.
47. Kraut, E.H., Bouroncle, B.A. & Grever, M.R. (1989) Pentostatin in the treatment of advanced hairy cell leukemia. Journal of Clinical Oncology, 7, 168–172.
48. Kreitman, R.J. & Pastan, I. (2011) Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clinical Cancer Research, 17, 6398–6405.
49. Kreitman, R.J., Wilson, W.H., Bergeron, K., Raggio, M., Stetler-Stevenson, M., FitzGerald, D.J. & Pastan, I. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. New England Journal of Medicine, 345, 241–247.
50. Kreitman, R.J., Wilson, W., Calvo, K.R., Arons, E., Roth, L., Sapolsky, J., Zhou, H., Raffeld, M. & Stetler-Stevenson, M. (2013) Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia. Clinical Cancer Research, 19, 6873–6881.
51. Kreitman, R.J., Arons, E., Tallman, M.S., Tadeusz, R., Coutre, S., Wilson, W.H., Stetler-Stevenson, M., Yuan, C.M., Lanasa, M., FitzGerald, D.J. & Pastan, I. (2015) High response rate of moxetumomab pasudotox in relapsed/refractory hairy cell leukemia includes eradication of minimal residual disease: potential importance for outcome. Blood, 126, 4161.
52. Lauria, F., Bocchia, M., Marotta, G., Raspadori, D., Zinzani, P.L. & Rondelli, D. (1997) Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications. Blood, 89, 1838–1839.
53. Machii, T., Chou, T., Suzuki, M., Ohe, Y., Katagiri, S., Kitano, E.K., Kitano, K., Fujiyama, Y., Izumi, T., Shimazaki, C., Nanba, K., Ohashi, Y. & Kitani, T.; Cladribine Study Group. (2005) Phase II clinical study of cladribine in the treatment of hairy cell leukemia. International Journal of Hematology, 82, 230–235.
54. Magee, M.J., McKenzie, S., Filippa, D.A., Arlin, Z.A., Gee, T.S. & Clarkson, B.D. (1985) Hairy cell leukemia. Durability of response to splenectomy in 26 patients and treatment of relapse with androgens in six patients. Cancer, 56, 2557–2562.
55. Maloisel, F., Benboubker, L., Gardembas, M., Coiffier, B., Divine, M., Sebban, C., Blanc, M., Abgrall, J.F., Lederlin, P., Harousseau, J.L., Blaise, A.M., Grosbois, B., Morice, P., Ghandour, C. & Castaigne, S. (2003) Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia, 17, 45–51.
56. Matsushita, K., Margulies, I., Onda, M., Nagata, S., Stetler-Stevenson, M. & Kreitman, R.J. (2008) Soluble CD22 as a tumor marker for hairy cell leukemia. Blood, 112, 2272–2277.
57. Matutes, E., Meeus, P., McLennan, K. & Catovsky, D. (1997) The significance of minimal residual disease in hairy cell leukaemia treated with deoxycoformycin: a long-term follow-up study. British Journal of Haematology, 98, 375–383.
58. Matutes, E., Wotherspoon, A., Brito-Babapulle, V. & Catovsky, D. (2001) The natural history and clinico-pathological features of the variant form of hairy cell leukemia. Leukemia, 15, 184–186.
59. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R.C., Lee, H., Chen, Z., Lee, M.K., Attar, N., Sazegar, H., Chodon, T., Nelson, S.F., McArthur, G., Sosman, J.A., Ribas, A. & Lo, R.S. (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 468, 973–977.
60. Nieva, J., Bethel, K. & Saven, A. (2003) Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood, 102, 810–813.
61. Palomera, L., Domingo, J.M., Sola, C., Azaceta, G., Calvo, M.T. & Gutierrez, M. (2002) Cladribine (2-chlorodeoxyadenosine) therapy in hairy cell leukemia variant. A report of three cases. Haematologica, 87, 107–108.
62. Pettirossi, V., Santi, A., Imperi, E., Russo, G., Pucciarini, A., Bigerna, B., Schiavoni, G., Fortini, E., Spanhol-Rosseto, A., Sportoletti, P., Mannucci, R., Martelli, M.P., Klein-Hitpass, L., Falini, B. & Tiacci, E. (2015) BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. Blood, 125, 1207–1216.
63. Pettitt, A.R. (2003) Mechanism of action of purine analogues in chronic lymphocytic leukaemia. British Journal of Haematology, 121, 692–702.
64. Rafel, M., Cervantes, F., Beltran, J.M., Zuazu, F., Hernandez Nieto, L., Rayon, C., Garcia Talavera, J. & Montserrat, E. (2000) Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer, 88, 352–357.
65. Ratain, M.J., Golomb, H.M., Bardawil, R.G., Vardiman, J.W., Westbrook, C.A., Kaminer, L.S., Lembersky, B.C., Bitter, M.A. & Daly, K. (1987) Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood, 69, 872–877.
66. Ratain, M.J., Golomb, H.M., Vardiman, J.W., Westbrook, C.A., Barker, C., Hooberman, A., Bitter, M.A. & Daly, K. (1988) Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables. Journal of Clinical Oncology, 6, 1714–1721.
67. Ravandi, F., Jorgensen, J.L., O'Brien, S.M., Verstovsek, S., Koller, C.A., Faderl, S., Giles, F.J., Ferrajoli, A., Wierda, W.G., Odinga, S., Huang, X., Thomas, D.A., Freireich, E.J., Jones, D., Keating, M.J. & Kantarjian, H.M. (2006) Eradication of minimal residual disease in hairy cell leukemia. Blood, 107, 4658–4662.
68. Ravandi, F., O'Brien, S., Jorgensen, J., Pierce, S., Faderl, S., Ferrajoli, A., Koller, C., Challagundla, P., York, S., Brandt, M., Luthra, R., Burger, J., Thomas, D., Keating, M. & Kantarjian, H. (2011) Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood, 118, 3818–3823.
69. Rawstron, A.C., de Tute, R., Jack, A.S. & Hillmen, P. (2006) Flow cytometric protein expression profiling as a systematic approach for developing disease-specific assays: identification of a chronic lymphocytic leukaemia-specific assay for use in rituximab-containing regimens. Leukemia, 20, 2102–2110.
70. Ribeiro, P., Bouaffia, F., Peaud, P.Y., Blanc, M., Salles, B., Salles, G. & Coiffier, B. (1999) Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer, 85, 65–71.
71. Robak, T., Blasinska-Morawiec, M., Blonski, J., Hellmann, A., Halaburda, K., Konopka, L., Kotlarek-Haus, S., Potoczek, S., Hansz, J., Dmoszynska, A., Urasinski, I., Zdziarska, B., Dwilewicz-Trojaczek, J., Holowiecki, J. & Skotnicki, A.B. (1999) 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. European Journal of Haematology, 62, 49–56.
72. Robak, T., Jamroziak, K., Gora-Tybor, J., Blonski, J.Z., Kasznicki, M., Dwilewicz-Trojaczek, J., Wiater, E., Zdunczyk, A., Dybowicz, J., Dmoszynska, A., Wojtaszko, M., Zdziarska, B., Calbecka, M., Kostyra, A., Hellmann, A., Lewandowski, K., Stella-Holowiecka, B., Sulek, K., Gawronski, K., Skotnicki, A.B., Nowak, W., Zawilska, K., Molendowicz-Portala, L., Kloczko, J., Sokolowski, J., Warzocha, K., Seferynska, I., Ceglarek, B. & Konopka, L. (2007) Cladribine in a weekly versus daily schedule for untreated active hairy cell leukemia: final report from the Polish Adult Leukemia Group (PALG) of a prospective, randomized, multicenter trial. Blood, 109, 3672–3675.
73. Rosenberg, J.D., Burian, C., Waalen, J. & Saven, A. (2014) Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series. Blood, 123, 177–183.
74. Rummel, M.J. & Gregory, S.A. (2011) Bendamustine's emerging role in the management of lymphoid malignancies. Seminars in Hematology, 48, S24–S36.
75. Sausville, J.E., Salloum, R.G., Sorbara, L., Kingma, D.W., Raffeld, M., Kreitman, R.J., Imus, P.D., Venzon, D. & Stetler-Stevenson, M. (2003) Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. American Journal of Clinical Pathology, 119, 213–217.
76. Saven, A., Burian, C., Koziol, J.A. & Piro, L.D. (1998) Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood, 92, 1918–1926.
77. Saven, A., Burian, C., Adusumalli, J. & Koziol, J.A. (1999) Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. Blood, 93, 2471–2477.
78. + lymphocyte counts in patients with hairy cell leukemia. Blood, 83, 2906–2911.
79. + lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up. Leukemia, 11, 42–47.
80. Sharpe, R.W. & Bethel, K.J. (2006) Hairy cell leukemia: diagnostic pathology. Hematology/oncology Clinics of North America, 20, 1023–1049.
81. Sigal, D.S., Sharpe, R., Burian, C. & Saven, A. (2010) Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood, 115, 1893–1896.
82. Sivina, M., Kreitman, R.J., Arons, E., Ravandi, F. & Burger, J.A. (2014) The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach. British Journal of Haematology, 166, 177–188.
83. Smith, T.J., Bohlke, K., Lyman, G.H., Carson, K.R., Crawford, J., Cross, S.J., Goldberg, J.M., Khatcheressian, J.L., Leighl, N.B., Perkins, C.L., Somlo, G., Wade, J.L., Wozniak, A.J. & Armitage, J.O. (2015) Recommendations for the use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. Journal of Clinical Oncology, 33, 3199–3212.
84. Strati, P., Keating, M.J., O'Brien, S.M., Burger, J., Ferrajoli, A., Jain, N., Tambaro, F.P., Estrov, Z., Jorgensen, J., Challagundla, P., Faderl, S.H. & Wierda, W.G. (2014) Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood, 123, 3727–3732.
85. Tallman, M.S., Hakimian, D., Rademaker, A.W., Zanzig, C., Wollins, E., Rose, E. & Peterson, L.C. (1996) Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood, 88, 1954–1959.
86. Tetreault, S.A., Robbins, B.A. & Saven, A. (1999) Treatment of hairy cell leukemia-variant with cladribine. Leukaemia & Lymphoma, 35, 347–354.
87. Thomas, D.A., O'Brien, S., Bueso-Ramos, C., Faderl, S., Keating, M.J., Giles, F.J., Cortes, J. & Kantarjian, H.M. (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood, 102, 3906–3911.
88. Thompson, P.A., Tam, C.S., O'Brien, S.M., Wierda, W.G., Stingo, F., Plunkett, W., Smith, S.C., Kantarjian, H.M., Freireich, E.J. & Keating, M.J. (2016) Fludarabine, cyclophosphamide and rituximab achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood, 127, 303–309.
89. Tiacci, E., Trifonov, V., Schiavoni, G., Holmes, A., Kern, W., Martelli, M.P., Pucciarini, A., Bigerna, B., Pacini, R., Wells, V.A., Sportoletti, P., Pettirossi, V., Mannucci, R., Elliott, O., Liso, A., Ambrosetti, A., Pulsoni, A., Forconi, F., Trentin, L., Semenzato, G., Inghirami, G., Capponi, M., Di Raimondo, F., Patti, C., Arcaini, L., Musto, P., Pileri, S., Haferlach, C., Schnittger, S., Pizzolo, G., Foa, R., Farinelli, L., Haferlach, T., Pasqualucci, L., Rabadan, R. & Falini, B. (2011) BRAF mutations in hairy-cell leukemia. New England Journal of Medicine, 364, 2305–2315.
90. Tiacci, E., Park, J.H., De Carolis, L., Chung, S.S., Broccoli, A., Scott, S., Zaja, F., Devlin, S., Pulsoni, A., Chung, Y.R., Cimminiello, M., Kim, E., Rossi, D., Stone, R.M., Motta, G., Saven, A., Varettoni, M., Altman, J.K., Anastasia, A., Grever, M.R., Ambrosetti, A., Rai, K.R., Fraticelli, V., Lacouture, M.E., Carella, A.M., Levine, R.L., Leoni, P., Rambaldi, A., Falzetti, F., Ascani, S., Capponi, M., Martelli, M.P., Park, C.Y., Pileri, S.A., Rosen, N., Foa, R., Berger, M.F., Zinzani, P.L., Abdel-Wahab, O., Falini, B. & Tallman, M.S. (2015) Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia. New England Journal of Medicine, 373, 1733–1747.
91. Van Norman, A.S., Nagorney, D.M., Martin, J.K., Phyliky, R.L. & Ilstrup, D.M. (1986) Splenectomy for hairy cell leukemia. A clinical review of 63 patients. Cancer, 57, 644–648.
92. Waterfall, J.J., Arons, E., Walker, R.L., Pineda, M., Roth, L., Killian, J.K., Abaan, O.D., Davis, S.R., Kreitman, R.J. & Meltzer, P.S. (2014) High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias. Nature Genetics, 46, 8–10.
93. Wheaton, S., Tallman, M.S., Hakimian, D. & Peterson, L. (1996) Minimal residual disease may predict bone marrow relapse in patients with hairy cell leukemia treated with 2-chlorodeoxyadenosine. Blood, 87, 1556–1560.
94. Xi, L., Arons, E., Navarro, W., Calvo, K.R., Stetler-Stevenson, M., Raffeld, M. & Kreitman, R.J. (2012) Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood, 119, 3330–3332.
95. Zinzani, P.L., Tani, M., Marchi, E., Stefoni, V., Alinari, L., Musuraca, G., Gabriele, A., Pileri, S. & Baccarani, M. (2004) Long-term follow-up of front-line treatment of hairy cell leukemia with 2-chlorodeoxyadenosine. Haematologica, 89, 309–313.